Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - methylphenidate hydrochloride, quantity: 36 mg - tablet, modified release - excipient ingredients: triethyl citrate; methacrylic acid copolymer; lactose monohydrate; hypromellose; colloidal anhydrous silica; purified talc; magnesium stearate; fumaric acid; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid; titanium dioxide; polyvinyl alcohol; macrogol 3350 - methylphenidate-teva xr is indicated for the treatment of attention deficit hyperactivity disorder (adhd). treatment should be commenced by a specialist.,a diagnosis of attention deficit hyperactivity disorder (adhd; dsm-iv) implies the presence of hyperactive-impulsive or inattentive symptoms that caused impairment and were present before age 7 years.,need for comprehensive treatment programme methylphenidate-teva xr is indicated as an integral part of a total treatment program for adhd that may include other measures (psychological, educational and social) for patients with this syndrome. stimulants are not intended for use in the patient who exhibits symptoms secondary to environmental factors and/or other primary psychiatric disorders, including psychosis. appropriate educational placement is essential and psychosocial intervention is often helpful. when remedial measures alone are insufficient, the decision to prescribe stimulant medication will depend upon the physician?s assessment of the chronicity and severity of the patient?s symptoms.,long term use the effectiveness of methylphenidate hydrochloride extended release tablets for long-term use has not been systematically evaluated in controlled trials. therefore the physician who elects to use methylphenidate-teva xr for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - methylphenidate hydrochloride, quantity: 54 mg - tablet, modified release - excipient ingredients: purified talc; colloidal anhydrous silica; methacrylic acid copolymer; fumaric acid; magnesium stearate; lactose monohydrate; triethyl citrate; hypromellose; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid; titanium dioxide; iron oxide red; polyvinyl alcohol; macrogol 3350 - methylphenidate-teva xr is indicated for the treatment of attention deficit hyperactivity disorder (adhd). treatment should be commenced by a specialist.,a diagnosis of attention deficit hyperactivity disorder (adhd; dsm-iv) implies the presence of hyperactive-impulsive or inattentive symptoms that caused impairment and were present before age 7 years.,need for comprehensive treatment programme methylphenidate-teva xr is indicated as an integral part of a total treatment program for adhd that may include other measures (psychological, educational and social) for patients with this syndrome. stimulants are not intended for use in the patient who exhibits symptoms secondary to environmental factors and/or other primary psychiatric disorders, including psychosis. appropriate educational placement is essential and psychosocial intervention is often helpful. when remedial measures alone are insufficient, the decision to prescribe stimulant medication will depend upon the physician?s assessment of the chronicity and severity of the patient?s symptoms.,long term use the effectiveness of methylphenidate hydrochloride extended release tablets for long-term use has not been systematically evaluated in controlled trials. therefore the physician who elects to use methylphenidate-teva xr for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - amlodipine besilate, quantity: 6.9335 mg (equivalent: amlodipine, qty 5 mg) - tablet, uncoated - excipient ingredients: mannitol; microcrystalline cellulose; magnesium stearate; colloidal anhydrous silica; sodium starch glycollate - hypertension: amlo 5 tablets are indicated for the first line treatment of hypertension and can be used as the sole agent to control blood pressure in the majority of patients. patients not adequately controlled on a single antihypertensive agent may benefit from the addition of amlodipine, which has been used in combination with a thiazide diuretic, beta adrenoreceptor blocking agent or an angiotensin-converting enzyme inhibitor. angina: amlo 5 tablets are indicated for the first line treatment of chronic stable angina. amlo 5 tablets may be used alone, as monotherapy or in combination with other antianginal drugs.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - amlodipine besilate, quantity: 6.9335 mg (equivalent: amlodipine, qty 5 mg) - tablet, uncoated - excipient ingredients: mannitol; microcrystalline cellulose; magnesium stearate; colloidal anhydrous silica; sodium starch glycollate - hypertension: amlodipine gh tablets are indicated for the first line treatment of hypertension and can be used as the sole agent to control blood pressure in the majority of patients. patients not adequately controlled on a single antihypertensive agent may benefit from the addition of amlodipine, which has been used in combination with a thiazide diuretic, beta adrenoreceptor blocking agent or an angiotensin-converting enzyme inhibitor. angina: amlodipine gh tablets are indicated for the first line treatment of chronic stable angina. amlodipine gh tablets may be used alone, as monotherapy or in combination with other antianginal drugs.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - amlodipine besilate, quantity: 13.868 mg (equivalent: amlodipine, qty 10 mg) - tablet, uncoated - excipient ingredients: calcium hydrogen phosphate; sodium starch glycollate type a; microcrystalline cellulose; magnesium stearate - hypertension: amlodipine-ga tablets are indicated for the first line treatment of hypertension and can be used as the sole agent to control blood pressure in the majority of patients. patients not adequately controlled on a single antihypertensive agent may benefit from the addition of amlodipine, which has been used in combination with a thiazide diuretic, beta adrenoceptor blocking agent or an angiotensin-converting enzyme inhibitor. angina: amlodipine-ga tablets are indicated for the first line treatment of chronic stable angina. amlodipine-ga may be used alone, as monotherapy or in combination with other antianginal drugs.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - amlodipine besilate, quantity: 6.934 mg (equivalent: amlodipine, qty 5 mg) - tablet, uncoated - excipient ingredients: calcium hydrogen phosphate; magnesium stearate; microcrystalline cellulose; sodium starch glycollate type a - hypertension: amlodipine-ga tablets are indicated for the first line treatment of hypertension and can be used as the sole agent to control blood pressure in the majority of patients. patients not adequately controlled on a single antihypertensive agent may benefit from the addition of amlodipine, which has been used in combination with a thiazide diuretic, beta adrenoceptor blocking agent or an angiotensin-converting enzyme inhibitor. angina: amlodipine-ga tablets are indicated for the first line treatment of chronic stable angina. amlodipine-ga may be used alone, as monotherapy or in combination with other antianginal drugs.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - carvedilol, quantity: 12.5 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose monohydrate; crospovidone; povidone; colloidal anhydrous silica; magnesium stearate; titanium dioxide; macrogol 8000; hypromellose; polydextrose; triethyl citrate - dicarz is indicated for the treatment of hypertension. data have not been provided to support the use of this drug in renovascular disease. dicarz is indicated for the treatment of patients with symptomatic mild to severe (nyha class ii -iv) congestive heart failure (chf) as an adjunct to conventional treatments (e.g. diuretics, digoxin, ace inhibitors and vasodilators).

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - carvedilol, quantity: 6.25 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose monohydrate; crospovidone; povidone; colloidal anhydrous silica; magnesium stearate; titanium dioxide; macrogol 8000; hypromellose; polydextrose; triethyl citrate - dicarz is indicated for the treatment of hypertension. data have not been provided to support the use of this drug in renovascular disease. dicarz is indicated for the treatment of patients with symptomatic mild to severe (nyha class ii -iv) congestive heart failure (chf) as an adjunct to conventional treatments (e.g. diuretics, digoxin, ace inhibitors and vasodilators).

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - carvedilol, quantity: 25 mg - tablet, film coated - excipient ingredients: magnesium stearate; microcrystalline cellulose; lactose monohydrate; colloidal anhydrous silica; crospovidone; povidone; titanium dioxide; macrogol 8000; hypromellose; polydextrose; triethyl citrate - carvedilol is indicated for the treatment of hypertension. data have not been provided to support the use of this drug in renovascular disease. carvedilol is indicated for the treatment of patients with symptomatic mild to severe (nyha class ii to iv) congestive heart failure (chf) as an adjunct to conventional treatments (e.g. diuretics, digoxin, ace inhibitors and vasodilators).

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - carvedilol, quantity: 12.5 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; colloidal anhydrous silica; lactose monohydrate; povidone; crospovidone; magnesium stearate; titanium dioxide; macrogol 8000; hypromellose; polydextrose; triethyl citrate - carvedilol is indicated for the treatment of hypertension. data have not been provided to support the use of this drug in renovascular disease. carvedilol is indicated for the treatment of patients with symptomatic mild to severe (nyha class ii to iv) congestive heart failure (chf) as an adjunct to conventional treatments (e.g. diuretics, digoxin, ace inhibitors and vasodilators).